日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer

一项针对晚期胰腺癌或结直肠癌患者的BMS-813160(一种CCR2/5双重拮抗剂)联合化疗或纳武利尤单抗的1b/2期研究

Le, Dung T; Folprecht, Gunnar; Varghese, Anna M; Gutierrez, Martin; Noel, Marcus; Trikalinos, Nikolaos A; Chen, Eric; Dayyani, Farshid; Davis, S Lindsey; Ma, Wen Wee; BasuMallick, Atrayee; Garrido-Laguna, Ignacio; Osawa, Mayu; O'Brien, Shaun; Novosiadly, Ruslan D; Xu, Ke; Greenawalt, Danielle M; Dutta, Santanu; Twyman Saint Victor, Christina; Lenz, Heinz-Josef

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer

化疗与先天免疫激动剂协同作用可增强胰腺癌中T细胞的启动,从而促进免疫检查点抑制剂治疗。

Niu, Nan; Li, Keyu; Wang, Junke; Funes, Vanessa; Espinoza, Birginia; Li, Pan; Wang, Jianxin; Lyman, Melissa; He, Mengni; Herbst, Brian; Wichroski, Michael; Novosiadly, Ruslan; Shoucair, Sami; Mou, Yiping; Zheng, Lei

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors

BMS-986299(一种 NLRP3 激动剂)单药治疗以及与纳武利尤单抗和伊匹木单抗联合治疗晚期实体瘤患者的 I 期研究

Nelson, Blessie E; O'Brien, Shaun; Sheth, Rahul A; Hong, David S; Naing, Aung; Zhang, Xiaoping; Xu, Amy; Hamuro, Lora; Suryawanshi, Rasika; McKinley, Derrick; Novosiadly, Ruslan D; Piha-Paul, Sarina A

Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors

BMS-986156(一种糖皮质激素诱导的TNF受体相关蛋白激动剂)单独使用或与纳武利尤单抗联合使用治疗晚期实体瘤患者的药效学活性

Wang, R; Baxi, V; Li, Z; Locke, D; Hedvat, C; Sun, Y; Walsh, A M; Shao, X; Basavanhally, T; Greenawalt, D M; Patah, P; Novosiadly, R

Application of Pharmacokinetic/Pharmacodynamic Modeling to Bridge Mouse Antitumor Efficacy and Monkey Toxicology Data for Determining the Therapeutic Index of an Interleukin-10 Fc Fusion Protein.

应用药代动力学/药效学模型连接小鼠抗肿瘤疗效和猴子毒理学数据,以确定白细胞介素-10 Fc融合蛋白的治疗指数

Yang Zheng, Loy James, Poirson Brian, Dai Yanshan, Rajendran Surendran, Xu Shihua, Spires Vanessa, Gururajan Murali, Lin Zheng, Arbanas Jaren, Carl Stephen, Pace Samantha, Wang Yun, Mehl John, Vasudevan Krishna, Spires Thomas, Novosiadly Ruslan, Coker Shodeinde, Perez Raymond, Covello Kelly, Morin Paul, Graziano Robert, Broz Miranda, Lehman-McKeeman Lois

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery

SITC癌症免疫疗法资源文件:生物标志物发现领域的指南针

Hu-Lieskovan, Siwen; Bhaumik, Srabani; Dhodapkar, Kavita; Grivel, Jean-Charles J B; Gupta, Sumati; Hanks, Brent A; Janetzki, Sylvia; Kleen, Thomas O; Koguchi, Yoshinobu; Lund, Amanda W; Maccalli, Cristina; Mahnke, Yolanda D; Novosiadly, Ruslan D; Selvan, Senthamil R; Sims, Tasha; Zhao, Yingdong; Maecker, Holden T

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.

集落刺激因子-1受体抑制剂在晚期难治性乳腺癌或前列腺癌患者中的免疫调节活性:一项I期研究

Autio Karen A, Klebanoff Christopher A, Schaer David, Kauh John Sae Wook, Slovin Susan F, Adamow Matthew, Blinder Victoria S, Brahmachary Manisha, Carlsen Michelle, Comen Elizabeth, Danila Daniel C, Doman Thompson N, Durack Jeremy C, Fox Josef J, Gluskin Jill S, Hoffman David M, Kang Suhyun, Kang Praneet, Landa Jonathan, McAndrew Philomena F, Modi Shanu, Morris Michael J, Novosiadly Ruslan, Rathkopf Dana E, Sanford Rachel, Chapman Sonya C, Tate Courtney M, Yu Danni, Wong Phillip, McArthur Heather L

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

结直肠癌患者对西妥昔单抗的内在和获得性耐药性的基因组表征

Steven M Bray, Jeeyun Lee, Seung Tae Kim, Joon Young Hur, Philip J Ebert, John N Calley, Isabella H Wulur, Thejaswini Gopalappa, Swee Seong Wong, Hui-Rong Qian, Jason C Ting, Jiangang Liu, Melinda D Willard, Ruslan D Novosiadly, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Amit Aggarwal,

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

更正:拮抗剂抗PD-L1单克隆抗体LY3300054的发现和临床前表征

Li, Yiwen; Carpenito, Carmine; Wang, George; Surguladze, David; Forest, Amelie; Malabunga, Maria; Murphy, Mary; Zhang, Yiwei; Sonyi, Andreas; Chin, Darin; Burtrum, Douglas; Inigo, Ivan; Pennello, Anthony; Shen, Leyi; Malherbe, Laurent; Chen, Xinlei; Hall, Gerald; Haidar, Jaafar N; Ludwig, Dale L; Novosiadly, Ruslan D; Kalos, Michael

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

galunisertib(一种 TGFβRI 小分子抑制剂)靶向 TGFβ 通路,可促进抗肿瘤免疫,从而产生持久、完全的缓解,可作为单一疗法或与检查点阻断联合使用

Rikke B Holmgaard, David A Schaer, Yanxia Li, Stephen P Castaneda, Mary Y Murphy, Xiaohong Xu, Ivan Inigo, Julie Dobkin, Jason R Manro, Philip W Iversen, David Surguladze, Gerald E Hall, Ruslan D Novosiadly, Karim A Benhadji, Gregory D Plowman, Michael Kalos, Kyla E Driscoll